Skip to main content
Erschienen in: Cancer Causes & Control 8/2008

01.10.2008 | Original Paper

Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study

verfasst von: Yung-Kai Huang, Ya-Li Huang, Yu-Mei Hsueh, Mo-Hsiung Yang, Meei-Maan Wu, Shu-Yuan Chen, Ling-I Hsu, Chien-Jen Chen

Erschienen in: Cancer Causes & Control | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

The risk of urothelial carcinoma (UC) and urinary arsenic speciation have been evaluated in a few case–control studies; however, the association has not been verified in a prospective cohort study. The aim of this study was to examine the association between urinary arsenic speciation and the incidence of UC in a cohort study. A total of 1,078 residents of southwestern Taiwan were followed for an average of 12 years. A high-performance liquid chromatography/hydride generator and an atomic absorption spectrometry were used to measure urinary arsenite, arsenate, monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMAV). The incidence of UC was estimated by examining the National Cancer Registry of Taiwan between January 1985 and December 2001. There were 37 newly diagnosed cases of UC during a follow-up period of 11,655 person-years. Significantly higher percentages of MMAV and lower percentages of DMAV existed among the patients with UC than among the healthy residents. After adjustment for age, gender, educational level, and smoking status, the percentage of urinary DMAV was shown to have an inverse association with the risk of UC, having a relative risk (RR) of the tertile strata of 1.0, 0.3, and 0.3, respectively (p < 0.05 for the trend test). The RR (95% confidence interval) of residents with a cumulative arsenic exposure (CAE) of ≥20 mg/l-year and a higher percentage of MMAV or a CAE of ≥20 mg/l-year and a lower percentage of DMAV was 3.7 (1.2–11.6) or 4.2 (1.3–13.4) compared to residents with a CAE of <20 mg/l-year and a lower percentage of MMAV or a CAE of <20 mg/l-year and a higher percentage of DMAV respectively. There was a significant association between inefficient arsenic methylation and the development of UC in the residents in the high CAE exposure strata in an area of southwestern Taiwan endemic for arseniasis.
Literatur
1.
Zurück zum Zitat IARC (1980) Some metals and metallic compounds. International Agency for Research on Cancer, Lyon, Franch, p 325 IARC (1980) Some metals and metallic compounds. International Agency for Research on Cancer, Lyon, Franch, p 325
2.
Zurück zum Zitat Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45:5895–5899PubMed Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45:5895–5899PubMed
3.
Zurück zum Zitat Chen CJ, Chen CW, Wu MM, Kuo TL (1992) Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888–892PubMed Chen CJ, Chen CW, Wu MM, Kuo TL (1992) Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888–892PubMed
4.
Zurück zum Zitat Chiou HY, Hsueh YM, Liaw KF et al (1995) Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 55:1296–1300PubMed Chiou HY, Hsueh YM, Liaw KF et al (1995) Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 55:1296–1300PubMed
5.
Zurück zum Zitat National Research Council (2001) Arsenic in drinking water: 2001 update. National Academy Press, Washington, DC National Research Council (2001) Arsenic in drinking water: 2001 update. National Academy Press, Washington, DC
6.
Zurück zum Zitat Tapio S, Grosche B (2006) Arsenic in the aetiology of cancer. Mutat Res -Rev Mutat Res 612:215–246 Tapio S, Grosche B (2006) Arsenic in the aetiology of cancer. Mutat Res -Rev Mutat Res 612:215–246
7.
Zurück zum Zitat Smith AH, Goycolea M, Haque R, Biggs ML (1998) Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660–669PubMed Smith AH, Goycolea M, Haque R, Biggs ML (1998) Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660–669PubMed
8.
Zurück zum Zitat Marshall G, Ferreccio C, Yuan Y et al (2007) Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99:920–928PubMedCrossRef Marshall G, Ferreccio C, Yuan Y et al (2007) Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99:920–928PubMedCrossRef
9.
Zurück zum Zitat HopenhaynRich C, Biggs ML, Fuchs A et al (1996) Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 7:117–124CrossRef HopenhaynRich C, Biggs ML, Fuchs A et al (1996) Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 7:117–124CrossRef
10.
Zurück zum Zitat Vahter M (1981) Biotransformation of trivalent and pentavalent inorganic arsenic in mice and rats. Environ Res 25:286–293PubMedCrossRef Vahter M (1981) Biotransformation of trivalent and pentavalent inorganic arsenic in mice and rats. Environ Res 25:286–293PubMedCrossRef
11.
12.
Zurück zum Zitat Buchet JP, Lauwerys R, Roels H (1981) Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int Arch Occup Environ Health 48:71–79PubMedCrossRef Buchet JP, Lauwerys R, Roels H (1981) Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int Arch Occup Environ Health 48:71–79PubMedCrossRef
13.
Zurück zum Zitat Buchet JP, Lauwerys R, Roels H (1981) Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health 48:111–118PubMedCrossRef Buchet JP, Lauwerys R, Roels H (1981) Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health 48:111–118PubMedCrossRef
14.
Zurück zum Zitat Vahter M (1999) Methylation of inorganic arsenic in different mammalian species and population groups. Sci Progr 82:69–88 Vahter M (1999) Methylation of inorganic arsenic in different mammalian species and population groups. Sci Progr 82:69–88
15.
Zurück zum Zitat Styblo M, Del Razo LM, Vega L et al (2000) Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289–299PubMedCrossRef Styblo M, Del Razo LM, Vega L et al (2000) Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289–299PubMedCrossRef
16.
Zurück zum Zitat Petrick JS, Jagadish B, Mash EA, Aposhian HV (2001) Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol 14:651–656PubMedCrossRef Petrick JS, Jagadish B, Mash EA, Aposhian HV (2001) Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol 14:651–656PubMedCrossRef
17.
Zurück zum Zitat Nesnow S, Roop BC, Lambert G et al (2002) DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol 15:1627–1634PubMedCrossRef Nesnow S, Roop BC, Lambert G et al (2002) DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol 15:1627–1634PubMedCrossRef
18.
Zurück zum Zitat Chen YC, Su HJ, Guo YL et al (2003) Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14:303–310PubMedCrossRef Chen YC, Su HJ, Guo YL et al (2003) Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14:303–310PubMedCrossRef
19.
Zurück zum Zitat Chen YC, Guo YL, Su HJ et al (2003) Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241–248PubMedCrossRef Chen YC, Guo YL, Su HJ et al (2003) Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241–248PubMedCrossRef
20.
Zurück zum Zitat Hsueh YM, Chiou HY, Huang YL et al (1997) Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 6:589–596PubMed Hsueh YM, Chiou HY, Huang YL et al (1997) Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 6:589–596PubMed
21.
Zurück zum Zitat Yu RC, Hsu KH, Chen CJ, Froines JR (2000) Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9:1259–1262PubMed Yu RC, Hsu KH, Chen CJ, Froines JR (2000) Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9:1259–1262PubMed
22.
Zurück zum Zitat Pu YS, Yang SM, Huang YK et al (2007) Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol 218:99–106PubMedCrossRef Pu YS, Yang SM, Huang YK et al (2007) Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol 218:99–106PubMedCrossRef
23.
Zurück zum Zitat Steinmaus C, Bates MN, Yuan Y et al (2006) Arsenic methylation and bladder cancer risk in case–control studies in Argentina and the United States. J Occup Environ Med 48:478–488PubMedCrossRef Steinmaus C, Bates MN, Yuan Y et al (2006) Arsenic methylation and bladder cancer risk in case–control studies in Argentina and the United States. J Occup Environ Med 48:478–488PubMedCrossRef
24.
Zurück zum Zitat Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intra individual variability in Arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924PubMedCrossRef Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intra individual variability in Arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924PubMedCrossRef
25.
Zurück zum Zitat Hindmarsh JT (2002) Caveats in hair analysis in chronic arsenic poisoning. Clin Biochem 35:1–11PubMedCrossRef Hindmarsh JT (2002) Caveats in hair analysis in chronic arsenic poisoning. Clin Biochem 35:1–11PubMedCrossRef
26.
Zurück zum Zitat Hughes MF (2006) Biomarkers of exposure: a case study with inorganic arsenic. Environ Health Perspect 114:1790–1796PubMed Hughes MF (2006) Biomarkers of exposure: a case study with inorganic arsenic. Environ Health Perspect 114:1790–1796PubMed
27.
Zurück zum Zitat Wu HY, Chen KP, Tseng WP, Hsu CL (1961) Epidemiologic studies on blackfoot disease: I. Prevalence and incidence of the disease by age, sex, occupation and geographical distribution. Mem College Med Natl Taiwan Univ 7:33–50 Wu HY, Chen KP, Tseng WP, Hsu CL (1961) Epidemiologic studies on blackfoot disease: I. Prevalence and incidence of the disease by age, sex, occupation and geographical distribution. Mem College Med Natl Taiwan Univ 7:33–50
28.
Zurück zum Zitat Chen CJ, Hsueh YM, Lai MS et al (1995) Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53–60PubMed Chen CJ, Hsueh YM, Lai MS et al (1995) Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53–60PubMed
29.
Zurück zum Zitat Chen CJ, You SL, Lin LH, Hsu WL, Yang YW (2002) Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 32:S66–S81PubMedCrossRef Chen CJ, You SL, Lin LH, Hsu WL, Yang YW (2002) Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 32:S66–S81PubMedCrossRef
30.
Zurück zum Zitat US Department of Health, Human Services (2001) International classification of diseases, ninth revision, clinical modification. US Public Health Service, Washington, DC US Department of Health, Human Services (2001) International classification of diseases, ninth revision, clinical modification. US Public Health Service, Washington, DC
31.
Zurück zum Zitat SEER Program NCI (2001) Conversion of morphology of ICD-O-2 to ICD-O-3. In: Percy C, Fritz A, Ries L (eds) National Cancer Institute, Bethedsa, pp 1–160 SEER Program NCI (2001) Conversion of morphology of ICD-O-2 to ICD-O-3. In: Percy C, Fritz A, Ries L (eds) National Cancer Institute, Bethedsa, pp 1–160
32.
Zurück zum Zitat Hsueh YM, Huang YL, Huang CC et al (1998) Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A 54:431–444PubMedCrossRef Hsueh YM, Huang YL, Huang CC et al (1998) Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A 54:431–444PubMedCrossRef
33.
Zurück zum Zitat Kuo TL (1964) Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Rep Inst Pathol Natl Taiwan Univ 20:7–13 Kuo TL (1964) Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Rep Inst Pathol Natl Taiwan Univ 20:7–13
34.
Zurück zum Zitat Lo MC, Hsen YC, Lin BK (1977) Arsenic content of underground water in Taiwan: second report. Taiwan Provincial Institute of Environmental Sanitation, Taichung Lo MC, Hsen YC, Lin BK (1977) Arsenic content of underground water in Taiwan: second report. Taiwan Provincial Institute of Environmental Sanitation, Taichung
35.
Zurück zum Zitat Breslow NE, Day NE (1987) Statistical methods in cancer research. vol 2. The analysis of cohort studies. International Agency for Research on Cancer, Lyon, p 120 Breslow NE, Day NE (1987) Statistical methods in cancer research. vol 2. The analysis of cohort studies. International Agency for Research on Cancer, Lyon, p 120
36.
Zurück zum Zitat Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924PubMedCrossRef Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924PubMedCrossRef
37.
Zurück zum Zitat Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE (1996) Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect 104:620–628PubMedCrossRef Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE (1996) Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect 104:620–628PubMedCrossRef
38.
Zurück zum Zitat Hsueh YM, Hsu MK, Chiou HY, Yang MH, Huang CC, Chen CJ (2002) Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol Lett 133:83–91PubMedCrossRef Hsueh YM, Hsu MK, Chiou HY, Yang MH, Huang CC, Chen CJ (2002) Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol Lett 133:83–91PubMedCrossRef
39.
Zurück zum Zitat Concha G, Nermell B, Vahter MV (1998) Metabolism of inorganic arsenic in children with chronic high arsenic exposure in northern Argentina. Environ Health Perspect 106:355–359PubMedCrossRef Concha G, Nermell B, Vahter MV (1998) Metabolism of inorganic arsenic in children with chronic high arsenic exposure in northern Argentina. Environ Health Perspect 106:355–359PubMedCrossRef
40.
Zurück zum Zitat Vahter M, Concha G, Nermell B, Nilsson R, Dulout F, Natarajan AT (1995) A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol 293:455–462PubMedCrossRef Vahter M, Concha G, Nermell B, Nilsson R, Dulout F, Natarajan AT (1995) A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol 293:455–462PubMedCrossRef
41.
Zurück zum Zitat Chiou HY, Hsueh YM, Hsieh LL et al (1997) Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res -Rev Mutat Res 386:197–207 Chiou HY, Hsueh YM, Hsieh LL et al (1997) Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res -Rev Mutat Res 386:197–207
42.
Zurück zum Zitat Marnell LL, Garcia-Vargas GG, Chowdhury UK et al (2003) Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol 16:1507–1513PubMedCrossRef Marnell LL, Garcia-Vargas GG, Chowdhury UK et al (2003) Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol 16:1507–1513PubMedCrossRef
43.
Zurück zum Zitat Schmuck EM, Board PG, Whitbread AK et al (2005) Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer’s and Parkinson’s diseases. Pharmacogenet Genomics 15:493–501PubMedCrossRef Schmuck EM, Board PG, Whitbread AK et al (2005) Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer’s and Parkinson’s diseases. Pharmacogenet Genomics 15:493–501PubMedCrossRef
44.
Zurück zum Zitat Wood TC, Salavaggione OE, Mukherjee B et al (2006) Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem 281:7364–7373PubMedCrossRef Wood TC, Salavaggione OE, Mukherjee B et al (2006) Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem 281:7364–7373PubMedCrossRef
45.
Zurück zum Zitat Francesconi KA, Kuehnelt D (2004) Determination of arsenic species: a critical review of methods and applications, 2000–2003. Analyst 129:373–395PubMedCrossRef Francesconi KA, Kuehnelt D (2004) Determination of arsenic species: a critical review of methods and applications, 2000–2003. Analyst 129:373–395PubMedCrossRef
46.
Zurück zum Zitat Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176:127–144PubMedCrossRef Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176:127–144PubMedCrossRef
47.
Zurück zum Zitat Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D (2001) Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 172:225–232PubMedCrossRef Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D (2001) Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 172:225–232PubMedCrossRef
48.
Zurück zum Zitat Drobna Z, Jaspers I, Thomas DJ, Styblo M (2003) Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J 17:67–69PubMed Drobna Z, Jaspers I, Thomas DJ, Styblo M (2003) Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J 17:67–69PubMed
49.
Zurück zum Zitat Gong ZL, Lu XF, Cullen WR, Le XC (2001) Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J Anal At Spectrum 16:1409–1413CrossRef Gong ZL, Lu XF, Cullen WR, Le XC (2001) Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J Anal At Spectrum 16:1409–1413CrossRef
50.
Zurück zum Zitat Del Razo LM, Styblo M, Cullen WR, Thomas DJ (2001) Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 174:282–293PubMedCrossRef Del Razo LM, Styblo M, Cullen WR, Thomas DJ (2001) Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 174:282–293PubMedCrossRef
51.
Zurück zum Zitat Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG et al (2005) Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113:250–254PubMedCrossRef Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG et al (2005) Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113:250–254PubMedCrossRef
52.
Zurück zum Zitat Le XC, Cullen WR, Reimer KJ (1994) Human urinary arsenic excretion after one-time ingestion of seaweed, crab, and shrimp. Clin Chem 40:617–624PubMed Le XC, Cullen WR, Reimer KJ (1994) Human urinary arsenic excretion after one-time ingestion of seaweed, crab, and shrimp. Clin Chem 40:617–624PubMed
53.
Zurück zum Zitat Ma M, Le XC (1998) Effect of arsenosugar ingestion on urinary arsenic speciation. Clin Chem 44:539–550PubMed Ma M, Le XC (1998) Effect of arsenosugar ingestion on urinary arsenic speciation. Clin Chem 44:539–550PubMed
54.
Zurück zum Zitat Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924PubMedCrossRef Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924PubMedCrossRef
Metadaten
Titel
Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study
verfasst von
Yung-Kai Huang
Ya-Li Huang
Yu-Mei Hsueh
Mo-Hsiung Yang
Meei-Maan Wu
Shu-Yuan Chen
Ling-I Hsu
Chien-Jen Chen
Publikationsdatum
01.10.2008
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 8/2008
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9146-5

Weitere Artikel der Ausgabe 8/2008

Cancer Causes & Control 8/2008 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.